dMed-Clinipace is a merged global full-service CRO formed by the combination of dMed Global and Clinipace Incorporated. The company provides clinical development, regulatory, pharmacovigilance and clinical analytics services with therapeutic focus in oncology, rare disease, gastroenterology, nephrology and women’s health. Led by Global Chairman and CEO Dr. Lingshi Tan, the CRO supports end-to-end clinical programs. The Series C+ financing proceeds helped finance the merger announced in April 2021. The organization employs more than 1,700 staff across 22 offices in the Americas, Europe and Asia-Pacific, including over 700 staff in China. Investors from prior angel, A and B rounds have continued to increase their contributions since dMed’s inception in 2016. dMed is a full-service clinical CRO that provides consulting, regulatory affairs and strategy, early clinical development, clinical science and medical affairs, clinical operations, biostatistics and programming, data management, drug safety and pharmacovigilance, quality assurance and information solutions. The company leverages and integrates China’s new regulatory framework to offer innovative drug development strategies and help clients expand globally into the world’s second-largest pharmaceutical market. dMed says its collaboration models aim to raise efficiency in clinical R&D, shorten research cycles, and boost success rates for innovative pharma companies. It has established offices in major cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels. The company is led by Founder, Chairman and CEO Dr. Lingshi Tan and employs around 600 professionals globally. The business targets both Chinese and international pharmaceutical and medical device clients seeking to run clinical programs in China and worldwide. dMed is a global “next generation” full-service clinical CRO providing end-to-end industry solutions for pharmaceutical and medical device companies. Its offerings span consulting, early development and clinical pharmacology, clinical operations, biostatistics and programming, data management, safety and pharmacovigilance, clinical science, quality assurance, and regulatory affairs and strategy. The company has offices in major cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and employs more than 600 professionals globally. dMed completed the acquisition of Target Health, a New York-based CRO, mid-year to extend its global footprint and add technologies to its services. The company plans to use the new funding to accelerate expansion of its clinical operations and information technology infrastructure, and to extend global capacity in clinical development and product registration. Led by founder and CEO Dr. Lingshi Tan, dMed has attracted industry elites and experts in China and the US since its launch three years ago. dMed is a China-based contract research organization that provides comprehensive services to biopharmaceutical and medical device companies in China and globally. Its offerings include advising customers on clinical development plans, regulatory strategy, approval processes, and full clinical trial support. The company was founded in 2016 by Lingshi Tan. dMed raised $8M in a Series A round to support growth. It intends to use the funds to expand its assurance and clinical operations teams. Founder Lingshi Tan previously served as Pfizer’s Vice President of Worldwide Development Operations and Chairman and General Manager of Pfizer (China) R&D.

Total raised

$208M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2021